These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 5406970)

  • 21. [Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa?].
    Gauthier G; de Ajuriaguerra J; Geissbuhler F; Simona B; Constantinidis J; Yanniotis G; Krassoievitch M; Eisenring JJ; Tissot R
    Presse Med (1893); 1971 Jan; 79(3):91-2. PubMed ID: 5539694
    [No Abstract]   [Full Text] [Related]  

  • 22. [Dopa and decarboxylase inhibitors in Parkinson's disease].
    Pakkenberg H
    Ugeskr Laeger; 1974 Feb; 136(7):377. PubMed ID: 4821980
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa.
    Fermaglich J
    Med Ann Dist Columbia; 1974 Dec; 43(12):587-91. PubMed ID: 4532167
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of Parkinson's disease with L-DOPA and an association L-DOPA plus a DOPA decarboxylase inhibitor.
    Fazio C; Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Volante F
    Z Neurol; 1972; 202(4):347-55. PubMed ID: 4117654
    [No Abstract]   [Full Text] [Related]  

  • 25. Changes in taste under L-DOPA therapy.
    Siegfried J; Zumstein H
    Z Neurol; 1971; 200(4):345-8. PubMed ID: 4111634
    [No Abstract]   [Full Text] [Related]  

  • 26. [Cardiovascular effects of L-dopa and decarboxylase inhibitor on patients with Parkinson's disease].
    Desjacques P; Moret P; Gauthier G
    Schweiz Med Wochenschr; 1973 Dec; 103(50):1783-5. PubMed ID: 4129257
    [No Abstract]   [Full Text] [Related]  

  • 27. [Therapy of parkinsonism using a combination of L-dopa and decarboxylase inhibitor].
    Völler GW; Muschard F
    Med Welt; 1973 Apr; 24(17):705-7. PubMed ID: 4750934
    [No Abstract]   [Full Text] [Related]  

  • 28. Modification of levodopa effect by systemic decarboxylase inhibition.
    Mars H
    Arch Neurol; 1973 Feb; 28(2):91-5. PubMed ID: 4683155
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effect of a decarboxylase inhibitor (Ro 4-4602) and L-dopa on inhibited depressions. II. Experimental psychological studies].
    Pohlmeier H; Schön I; Matussek N
    Arzneimittelforschung; 1970 Jul; 20(7):932-3. PubMed ID: 4918920
    [No Abstract]   [Full Text] [Related]  

  • 30. [10 years of L-DOPA therapy of Parkinson's syndrome].
    Birkmayer W
    Wien Klin Wochenschr; 1971 Apr; 83(13):221-7. PubMed ID: 4254333
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor].
    Streifler M; Vardi J; Kesten M
    Harefuah; 1972 Nov; 83(9):362-4. PubMed ID: 4669737
    [No Abstract]   [Full Text] [Related]  

  • 32. [Treatment of Parkinson's disease with L-dopa alone or combined with Ro 4-4602].
    Barbeau A; Gillo-Joffroy L; Mars H; Arsenault A
    Rev Can Biol; 1972; 31():Suppl:169-74. PubMed ID: 5052323
    [No Abstract]   [Full Text] [Related]  

  • 33. [Modifications of catecholamine metabolism under the effect of a decarboxylase inhibitor associated with L-dopa and desipramine in patients with depressive and parkinsonian syndromes].
    Geissbuhler F; Bartholini G; Gaillard JM; Tissot R
    Encephale; 1971; 60(3):189-209. PubMed ID: 5119348
    [No Abstract]   [Full Text] [Related]  

  • 34. [Modalities of treatment of Parkinsonian syndrome with L-dopa].
    Yanniotis G; Eisenring JJ; Gauthier G; Tissot R; de Ajuriaguerra J
    Int J Neurol; 1972; 9(1):23-32. PubMed ID: 5086635
    [No Abstract]   [Full Text] [Related]  

  • 35. [Combination therapy of Parkinson's syndrome using L-dopa and a decarboxylase inhibitor].
    Fischer PA; Schneider E; Jacobi P; Maxion H
    Med Welt; 1973 Nov; 24(45):1742-6. PubMed ID: 4768206
    [No Abstract]   [Full Text] [Related]  

  • 36. [Decarboxylase inhibitor given in combination with l-dopa. A new therapeutic principal in parkinsonism].
    Dietrichson P
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2113-5. PubMed ID: 4590070
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor].
    Guillard A
    Brux Med; 1972 Oct; 52(10):673-80. PubMed ID: 4656191
    [No Abstract]   [Full Text] [Related]  

  • 38. [L-Dopa in Parkinson's-syndrome. New therapeutic attack?].
    Brockmann AW
    Ther Ggw; 1970 Nov; 109(11):1590-3. PubMed ID: 5486128
    [No Abstract]   [Full Text] [Related]  

  • 39. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1973; 9(6):349-62. PubMed ID: 4712542
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effects of additional medication of Amantadine sulfate in L-dopa-pretreated patients with Parkinson's syndrome (author's transl)].
    Schneider E; Fischer PA; Jacobi P
    Med Klin; 1974 Mar; 69(13):541-5. PubMed ID: 4831456
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.